IQVIA Holdings just delivered its Q2 earnings print, and the Street's response has been unambiguous — a wave of target-price raises landed on July 29, pushing the stock to $242.94, up 14% on the day and 20% on the week.
The analyst reaction is the story this week. Six firms raised targets within hours of the close, all maintaining positive ratings. JP Morgan lifted its target from $225 to $285 while holding Overweight. TD Cowen went to $288 from $233. Baird moved to $287 from $252. BMO Capital went to $270 from $210. Stifel raised to $276 from $220. RBC went to $247 from $221. The direction is unanimous — every recent move is upward. The consensus mean target now sits at $267, implying the stock is already running close to the middle of the freshly revised range. The one notable outlier on the board is Morgan Stanley, which downgraded to Equal-Weight in mid-June with a $200 target — that call now looks badly offside, and the question is how long before it gets revised. The bull case centers on improving client decision timelines, momentum in FSP and Real World Evidence segments, and a more constructive pricing environment. Bears had flagged constant currency growth decelerating to 3.8% from 6.8% last quarter — a valid concern heading into the print, but one the market has chosen to look through today.
The options market has pivoted sharply. The put/call ratio dropped to 0.92 on July 28, back in line with its 20-day average — a clean reset from the elevated readings above 1.15 that dominated the pre-earnings period. That prior hedging demand, flagged across multiple notes heading into the print, has unwound. The z-score of -0.20 confirms this is no longer a defensively positioned name. The borrow market has moved in the same direction: availability remains extraordinarily loose at roughly 4,945% — meaning there are nearly 50 shares available to borrow for every one shorted — and borrowing costs are negligible at 0.43%. Short interest has continued its steady retreat, now at 2.8% of free float, down nearly 9% over the past month. Nothing in the lending market presents friction for either direction.
The broader sector context matters here. CRL gained 7% on the day and is up nearly 10% on the week. FTRE rose 8% and ICLR added 7%. TMO gained 3% on the day and 10% on the week. The life sciences tools and CRO complex is moving together, which means IQV's 14% session gain is impressive even against a rising tide — the stock is not just riding the sector; it is leading it. MEDP is the one name bucking the trend, down 3% on the day despite a positive week, suggesting some stock-specific divergence in how the market is pricing CRO fundamentals.
Institutional ownership is broadly supportive. BlackRock holds 9% and added over 867,000 shares in the most recent reported period. JP Morgan Asset Management added 1.3 million shares. Artisan Partners built a position by 1.7 million shares. These are meaningful additions from quality holders, not passive drift. Insider activity is stale — the last reported trades were February sells at prices well below the current level — so that data adds nothing to the current read.
Valuation has moved with the price. The P/E now sits at 17.7x, up over 3 points in the past week and nearly 3.4 points over 30 days. EV/EBITDA has moved to 13x. Neither multiple looks stretched for a name where the growth debate has just shifted more constructively, though the factor score on EPS surprise ranks in only the 22nd percentile — suggesting the market has historically not rewarded beats here as consistently as in other names. The next earnings event is October 28, which is where the growth-rate debate will resume in earnest: one good quarter has calmed the deceleration narrative, but three months of data will determine whether 3.8% constant currency was a trough or a new floor.
The watch item heading into Q3 is whether R&DS revenue growth confirms the re-acceleration management is guiding for, and whether the Morgan Stanley Equal-Weight outlier gets revised — the gap between that $200 target and where the rest of the Street now sits is wide enough to be a live story on its own.
See the live data behind this article on ORTEX.
Open IQV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
